Five US-listed Dividend Kings—Johnson & Johnson, Procter & Gamble, Coca-Cola, Colgate-Palmolive, and Lowe's—have announced dividend increases and reported earnings reflecting resilience amid economic challenges like tariffs and currency swings. Johnson & Johnson raised dividends by 3.1% with strong revenue growth, while Procter & Gamble marked its 70th consecutive dividend hike despite some revenue misses. Coca-Cola showed standout growth with a raised outlook, Colgate-Palmolive benefited from pricing power, and Lowe's, despite a slight earnings miss, remains a long-term buy with a recent dividend increase. Investors should watch Lowe's upcoming earnings closely due to housing market concerns.
Johnson & Johnson and AbbVie both posted strong quarterly results but differ in dividend approach and business focus. J&J, a Dividend King with 64 years of raises, offers a modest 2.02% yield supported by diversified pharma and MedTech products. AbbV...
The iShares Core High Dividend ETF (HDV) relies heavily on energy and pharmaceutical sectors, with Exxon Mobil, Chevron, Johnson & Johnson, and AbbVie making up about 26% of its assets. Exxon and Johnson & Johnson are rated very safe due to strong ca...
Revolution Medicines closed at $205.55 on August 11, 2026, reaching a $44.1 billion market cap driven by its promising RAS-targeting oncology pipeline. The company has no current product revenue but shows strong clinical results, especially with dara...
Invesco's High Yield Equity Dividend Achievers ETF (PEY) uses a unique strategy by selecting stocks with at least 10 years of consecutive dividend growth before filtering for high yield. This approach avoids the pitfalls of pure yield-based ETFs that...
Johnson & Johnson shares trade near their 52-week high after a 55% rise, driven by strong revenue growth and promising drug sales. The company raised its full-year guidance, highlighting growth in key products like DARZALEX and TREMFYA. However, the ...
